Shopping Cart
Remove All
Your shopping cart is currently empty
Palivizumab (MEDI 493) is a humanized RSV-specific monoclonal antibody that selectively inhibits epitopes at the F protein A antigenic site of RSV subtypes A and B for the prevention of respiratory syncytial virus infection (RSV).

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $228 | In Stock | In Stock | |
| 5 mg | $578 | In Stock | In Stock | |
| 10 mg | $826 | - | In Stock | |
| 25 mg | $1,220 | - | In Stock | |
| 50 mg | $1,650 | - | In Stock | |
| 100 mg | $2,230 | - | In Stock |
| Description | Palivizumab (MEDI 493) is a humanized RSV-specific monoclonal antibody that selectively inhibits epitopes at the F protein A antigenic site of RSV subtypes A and B for the prevention of respiratory syncytial virus infection (RSV). |
| Synonyms | Synagis, MEDI 493 |
| Reactivity | Virus |
| Application | FACS Functional assay |
| Antibody Type | Monoclonal |
| Endotoxin | < 1.0 EU/mg |
| Conjucates | Unconjugated |
| Uniprot ID |
| Molecular Weight | 144.99 kDa |
| Cas No. | 188039-54-5 |
| Color | Transparent |
| Appearance | Liquid |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.